1,3-Beta-D-Glucan (BDG) Test: A Laboratory Specialist’s Complete Guide to Results and Interpretation

Written by a Board-Certified Laboratory Medicine Specialist (MD.PhD.)

In this article

1. What is 1,3-Beta-D-Glucan?
2. Reference ranges
3. Clinical interpretation
4. Limitations & false positives
5. Specialist’s perspective
6. References & image prompts

Quick summary: The 1,3-Beta-D-Glucan (BDG) test is a serum biomarker used to detect invasive fungal infections (IFI) in immunocompromised patients. A positive result (≥ 80 pg/mL) raises clinical suspicion for Candida, Aspergillus, or Pneumocystis jirovecii infection. Because false positives are common, the result must always be interpreted alongside clinical findings, imaging, and confirmatory tests — never in isolation.

1. What Is 1,3-Beta-D-Glucan?

1,3-Beta-D-Glucan (BDG) is a polysaccharide found in the cell walls of most pathogenic fungi. When a fungus invades human tissue, fragments of this cell-wall component leak into the bloodstream, making elevated serum BDG a useful surrogate marker of active infection.

The major fungi detected by BDG include:

• Candida spp. — most common cause of invasive fungal infection in ICU patients
• Aspergillus spp. — life-threatening mold in hematology patients
• Pneumocystis jirovecii — causes PCP pneumonia in HIV/AIDS and organ-transplant recipients
• Most other clinically significant fungi

Important exception: Cryptococcus neoformans and the Zygomycetes (Mucor, Rhizopus) have minimal BDG in their cell walls. A normal BDG result does not exclude these organisms. Dedicated testing (Cryptococcal antigen, Mucor PCR) is required when they are suspected.

Why is this test ordered?

• Early detection of invasive fungal infection — before blood cultures turn positive
• Monitoring of high-risk patients: hematopoietic stem cell transplant (HSCT) recipients, patients on prolonged corticosteroids or chemotherapy, solid organ transplant recipients
• Adjunctive tool to evaluate treatment response to antifungal therapy
• Non-invasive alternative when respiratory specimens for PCP diagnosis are difficult to obtain

2. Reference Ranges

The BDG test uses a colorimetric (Colorimetry) assay: patient serum is incubated with a chromogenic reagent. The polysaccharide triggers an enzymatic cascade that produces a measurable color change, quantified spectrophotometrically. The table below reflects widely used clinical cut-offs; always verify against your laboratory’s specific reagent system.

Result Category	BDG Level	Interpretation
Negative	< 60 pg/mL	IFI unlikely; low fungal burden
Indeterminate	60 – 79.9 pg/mL	Borderline; repeat testing and additional workup recommended
Positive	≥ 80 pg/mL	Consistent with invasive fungal infection; further evaluation required

* Reference ranges and cut-off values may vary by laboratory and reagent manufacturer. Always interpret results in the context of local laboratory standards.

3. Clinical Interpretation

High Positive result (≥ 80 pg/mL)

An elevated BDG supports the diagnosis of invasive fungal infection. Key conditions to consider:

• Invasive candidiasis — including candidemia and deep-seated Candida infections
• Invasive aspergillosis — typically in neutropenic or HSCT patients
• Pneumocystis jirovecii pneumonia (PJP/PCP) — BDG sensitivity is particularly high (often > 90%) in this condition, making it especially useful when BAL is not feasible
• Fusariosis, trichosporonosis, and other mold infections

Borderline Indeterminate result (60–79.9 pg/mL)

• Early or low-burden fungal infection
• Attenuated immune response preventing full antigenic release
• Partial antifungal effect in a patient already on prophylaxis

Recommended action: Repeat BDG within 3–5 days, obtain CT imaging, and consider Galactomannan (GM) testing or fungal PCR for further stratification.

Low Negative result (< 60 pg/mL)

• Low probability of most invasive fungal infections
• Does not exclude Cryptococcus or Zygomycetes (see caution above)
• A single negative in a high-risk patient warrants serial monitoring, not definitive reassurance

4. Precautions, Limitations, and False Positives

The BDG test has a meaningful false-positive rate. Clinicians must be aware of the following interfering factors before acting on a positive result:

Cause of False Positive	Mechanism
Hemodialysis with cellulose membranes	BDG leaches from the membrane material
Albumin or IVIG infusion	Glucan present in stabilizer excipients
Massive blood transfusion	BDG contamination from blood products
Certain beta-lactam antibiotics (e.g., amoxicillin-clavulanate, piperacillin-tazobactam)	Direct chemical interference with the chromogenic reagent
Blood culture bottle contamination	Non-sterile processing introduces environmental BDG
Severe bacterial sepsis	Gut permeability allows BDG translocation
Surgical gauze or other cellulose-based materials entering the bloodstream	Direct BDG release

Key principle: BDG is a screening biomarker, not a diagnostic gold standard. A single positive result should never prompt empirical antifungal therapy without corroborating clinical evidence. Two consecutive positive results on separate days significantly improve specificity and are preferred in most clinical guidelines.

Treatment monitoring caveat: BDG levels can remain elevated for days to weeks after initiating effective antifungal therapy. A persistently elevated BDG does not necessarily indicate treatment failure — clinical judgment and serial trending are essential.

5. Specialist’s Perspective & Conclusion

In my clinical experience, the BDG test delivers its greatest value as part of an integrated diagnostic strategy — not as a stand-alone decision driver. I routinely advise clinicians to think of BDG as an “early alert” system: a strongly positive result in a neutropenic patient with fever and a hazy chest CT should accelerate the diagnostic workup (CT-guided biopsy, bronchoalveolar lavage, Galactomannan), not substitute for it.

Two practical points I emphasize to residents and infectious disease colleagues:

1. Always ask about recent exposures before interpreting a positive BDG — specifically recent piperacillin-tazobactam use or hemodialysis, which are the most common sources of false elevation in the ICU.
2. For PJP in HIV patients, the BDG test is arguably its most powerful application. Sensitivity approaches 95%, and a clearly negative result in a non-immunosuppressed patient is genuinely reassuring.

Used thoughtfully, the BDG test is a valuable, non-invasive addition to the diagnostic toolkit for invasive fungal infection. Used carelessly, it generates anxiety, unnecessary antifungal therapy, and drug-related toxicity.

Author Profile

Laboratory Medicine Specialist, MD.PhD.

Board-certified specialist in clinical and laboratory medicine with expertise in infectious disease serology, fungal diagnostics, and biomarker interpretation. This article reflects current evidence-based guidelines as of April 2026. All medical decisions should be made in consultation with a qualified healthcare provider.

[MD.PhD.] Anti-TPO and Anti-Thyroglobulin Antibodies (2026) – MedLab Insight

[MD.PhD.] Understanding the CA19-9 Blood Test – MedLab Insight

References

1. Pappas, P. G., Kauffman, C. A., Andes, D. R., et al. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1–e50. https://doi.org/10.1093/cid/civ933
2. Patterson, T. F., Thompson, G. R., Denning, D. W., et al. (2016). Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the IDSA. Clinical Infectious Diseases, 63(4), e1–e60.
3. Karageorgopoulos, D. E., Qu, J. M., Korbila, I. P., et al. (2013). Accuracy of β-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clinical Microbiology and Infection, 19(1), 39–49.
4. Donnelly, J. P., Chen, S. C., Kauffman, C. A., et al. (2020). Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group. Clinical Infectious Diseases, 71(6), 1367–1376.
5. Clancy, C. J., & Nguyen, M. H. (2019). Diagnosing invasive candidiasis. Journal of Clinical Microbiology, 57(1), e01909-18.
6. UpToDate. (2025). Diagnosis of invasive candidiasis. Wolters Kluwer. https://www.uptodate.com
7. National Institutes of Health (NIH) — ClinicalInfo. (2024). Pneumocystis pneumonia (PCP). https://clinicalinfo.hiv.gov
8. https://pubmed.ncbi.nlm.nih.gov/29444828